ITOS iTeos Therapeutics: Multiplikator Forward P/S
iTeos Therapeutics (ITOS) is a promising player in immuno-oncology, developing breakthrough molecules to combat cancer. This chart of the company's future P/S visualizes market expectations, while 11.00 shows the current value of the metric. Stable demand for healthcare gives the asset defensive qualities, and the synergy between US and Belgian experts ensures the development of bold scientific ideas.
ITOS (iTeos Pharma): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas iTeos Therapeutics|ITOS - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas iTeos Therapeutics|ITOS - Gunggung kewajiban utang perusahaan|Utang marang nilai buku iTeos Pharma|ITOS - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan iTeos Therapeutics|Rasio cepet iteostherapeutics.com
- indikator pendapatan resik lan kelipatan nilai:
ITOS - Bathi pungkasan|Proyeksi bathi mangsa ngarep iTeos Therapeutics|ITOS - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep iTeos|ITOS - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA iTeos Pharma|ITOS - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan iTeos Therapeutics|ITOS - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan iteostherapeutics.com|ITOS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep iTeos Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis komprehensif perusahaan:iTeos Therapeutics, Inc. (ITOS)
The stability of iTeos Therapeutics (ITOS) is underpinned by R&D patent protection and strategic alliances with pharmaceutical behemoths, which establish a robust financial foundation. The forward P/S ratio trend reflects the relationship between market capitalization and expected sales, allowing investors to assess the premium paid for future growth and determine the fair balance between speculative expectations and the business's actual fundamental potential.
Pesaing wigati
Multiplikator Forward P/S ARGX (argenx)|BioNTech Inc. (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Abivax Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake ADMA Corp ADMA|PTGX (Protagonist Therapeutics) - Multiplikator forward rega marang pendapatan|IMVT: Rasio rega marang pendapatan sing dikarepake|KNSA (Kiniksa) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Grifols SA GRFS|Rasio rega marang prakiraan pendapatan Adaptive Biotechnologies Corp (ADPT)|CLDX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aurinia Pharmaceuticals AUPH|Rasio kapitalisasi marang dodolan sing dikarepake biocryst.com (BCRX)|VERA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan DNTH (Dianthus Therapeutics Inc)|PHVS (Pharvaris Corp) - Multiplikator forward rega marang pendapatan|ABCL: Rasio rega marang pendapatan sing dikarepake|TRML (Tourmaline Bio, Inc.) - Multiplikator Forward P/S|PGEN: Rega forward marang dodolan|Multiplikator Forward P/S PHAR|NKTR - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Upstream Bio Corp UPB|Rega forward marang dodolan ZBIO|Immunome, Inc. - Multiplikator Forward P/S|GOSS - Multiplikator Forward P/S|KalVista Pharmaceuticals, Inc. (KALV) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan SEPN (Septerna, Inc.)|PVLA (Pieris Pharmaceuticals Inc) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Savara Pharma SVRA|Multiplikator forward rega marang pendapatan RIGL (Rigel Pharmaceuticals)|Multiplikator Forward P/S anaptysbio.com (ANAB)|Astria Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake ENGN (enGene Holdings Inc)|RAPT Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Aerovate Therapeutics Inc JBIO|ACRS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan kyvernatx.com|Rasio rega marang prakiraan pendapatan Tiziana Life Sciences Ltd|Cabaletta Bio Inc. (CABA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S VTYX|Rasio kapitalisasi marang dodolan sing dikarepake Theratechnologies, Inc|Avalo Therapeutics, Inc - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake ELDN (eledon.com)|AGEN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Climb Bio Inc.|Zura Bio Limited (ZURA) - Rasio rega marang prakiraan pendapatan|ATYR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Adagene Inc|Ikena Oncology, Inc. - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S STTK|EQ (equilliumbio.com) - Rega forward marang dodolan|Multiplikator Forward P/S CNTB (Connect Biopharma Holdings Limited)|Multiplikator Forward P/S Immunic Therapeutics IMUX|ATRA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan IFRX (InflaRx N.V.)|X4 Pharmaceuticals, Inc. (XFOR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Adicet Bio, Inc.|CELU (Celularity Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S INmune Bio Corporation|Multiplikator forward rega marang pendapatan BRNS (Barinthus Biotherapeutics)|KZR (kezarlifesciences.com) - Rega forward marang dodolan|Multiplikator Forward P/S SABS (SAB Biotherapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Akari Therapeutics PLC (AKTX)|ENLV - Rasio rega marang prakiraan pendapatan|Q32 Bio Inc. (QTTB) - Multiplikator forward rega marang pendapatan|GeoVax Labs, Inc. (GOVX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan edesabiotech.com|Multiplikator forward rega marang pendapatan IBIO|Multiplikator Forward P/S Carisma Tx|Rasio rega marang prakiraan pendapatan XTL Biopharmaceuticals, Ltd. (XTLB)|boltbio.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S HCWB (HCW Biologics)|Aptevo Therapeutics, Inc. (APVO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|AIM ImmunoTech - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Aditxt ADTX|GRI (GRI Bio Corp) - Multiplikator forward rega marang pendapatan|XRTX: Rasio rega marang pendapatan sing dikarepake|HIND (Vyome Holdings Inc) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep revbiosciences.com REVB|Rasio rega marang prakiraan pendapatan Indaptus Therapeutics, Inc. (INDP)|SCNI - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan CalciMedica CALI|Rasio kapitalisasi marang dodolan sing dikarepake Affimed NV (AFMD)|ALLK: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan HOOK (HOOKIPA Pharma Inc.)|IGMS (igmbio.com) - Multiplikator forward rega marang pendapatan|OCEA: Rasio rega marang pendapatan sing dikarepake|TCBP (TC BioPharm (Holdings) PLC) - Multiplikator Forward P/S|THRD: Rega forward marang dodolan
